Carroll Financial Associates’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | $348K | Sell |
4,776
-4,145
| -46% | -$285K | 0.02% | 296 |
|
|
2021
Q3 | $623K | Buy |
8,921
+301
| +3% | +$21.1K | 0.03% | 235 |
|
|
2021
Q2 | $593K | Sell |
8,620
-1,052
| -11% | -$70.2K | 0.03% | 234 |
|
|
2021
Q1 | $625K | Sell |
9,672
-329
| -3% | -$21.2K | 0.04% | 222 |
|
|
2020
Q4 | $582K | Sell |
10,001
-951
| -9% | -$57.4K | 0.04% | 222 |
|
|
2020
Q3 | $692K | Buy |
10,952
+321
| +3% | +$22.3K | 0.05% | 183 |
|
|
2020
Q2 | $818K | Sell |
10,631
-3,535
| -25% | -$271K | 0.07% | 161 |
|
|
2020
Q1 | $1.06M | Buy |
14,166
+10,750
| +315% | +$743K | 0.1% | 124 |
|
|
2019
Q4 | $222K | Sell |
3,416
-2,304
| -40% | -$150K | 0.02% | 337 |
|
|
2019
Q3 | $362K | Buy |
5,720
+1,774
| +45% | +$116K | 0.03% | 264 |
|
|
2019
Q2 | $266K | Buy |
3,946
+724
| +22% | +$47.6K | 0.02% | 305 |
|
|
2019
Q1 | $209K | Buy |
3,222
+321
| +11% | +$21.3K | 0.02% | 317 |
|
|
2018
Q4 | $198K | Buy |
2,901
+16
| +0.6% | +$1.12K | 0.02% | 266 |
|
|
2018
Q3 | $222K | Sell |
2,885
-309
| -10% | -$23.3K | 0.02% | 267 |
|
|
2018
Q2 | $226K | Buy |
3,194
+631
| +25% | +$44.6K | 0.02% | 260 |
|
|
2018
Q1 | $193K | Buy |
2,563
+18
| +0.7% | +$1.43K | 0.02% | 274 |
|
|
2017
Q4 | $182K | Sell |
2,545
-1,964
| -44% | -$149K | 0.02% | 281 |
|
|
2017
Q3 | $376K | Sell |
4,509
-150
| -3% | -$11.5K | 0.04% | 187 |
|
|
2017
Q2 | $329K | Buy |
4,659
+54
| +1% | +$3.59K | 0.04% | 211 |
|
|
2017
Q1 | $312K | Sell |
4,605
-500
| -10% | -$35.2K | 0.04% | 209 |
|
|
2016
Q4 | $365K | Sell |
5,105
-135
| -3% | -$10K | 0.05% | 171 |
|
|
2016
Q3 | $414K | Buy |
5,240
+365
| +7% | +$29.6K | 0.06% | 160 |
|
|
2016
Q2 | $406K | Buy |
4,875
+60
| +1% | +$5.33K | 0.07% | 153 |
|
|
2016
Q1 | $442K | Buy |
4,815
+325
| +7% | +$29.3K | 0.08% | 142 |
|
|
2015
Q4 | $454K | Sell |
4,490
-173
| -4% | -$18K | 0.09% | 127 |
|
|
2015
Q3 | $474K | Buy |
4,663
+329
| +8% | +$36.5K | 0.11% | 120 |
|
|
2015
Q2 | $507K | Buy |
4,334
+2,988
| +222% | +$326K | 0.11% | 113 |
|
|
2015
Q1 | $132K | Buy |
1,346
+47
| +4% | +$4.77K | 0.06% | 170 |
|
|
2014
Q4 | $128K | Sell |
1,299
-2,535
| -66% | -$262K | 0.08% | 145 |
|
|
2014
Q3 | $414K | Buy |
3,834
+708
| +23% | +$69.3K | 0.13% | 103 |
|
|
2014
Q2 | $259K | Buy |
3,126
+150
| +5% | +$11.7K | 0.07% | 144 |
|
|
2014
Q1 | $211K | Buy |
2,976
+90
| +3% | +$7.06K | 0.07% | 146 |
|
|
2013
Q4 | $216K | Buy |
2,886
+135
| +5% | +$9.4K | 0.08% | 138 |
|
|
2013
Q3 | $172K | Buy |
2,751
+411
| +18% | +$24.6K | 0.06% | 150 |
|
|
2013
Q2 | $119K | Buy |
+2,340
| New | +$122K | 0.06% | 148 |
|
Other funds holding GILD
Carroll Financial Associates's GILD Position: Q4 2021 in Review
Carroll Financial Associates reduced its Gilead Sciences (GILD) stake by 46% in Q4 2021, selling an estimated $285K and leaving 4,776 shares worth $348K. The position accounts for 0.02% of the portfolio, ranked #296.
Carroll Financial Associates first reported a position in GILD in Q2 2013 and has held it in 35 quarters since. The position peaked at $1.06M in Q1 2020. 1,682 funds tracked by Wall St. Rank hold GILD as of Q4 2021.
- Carroll Financial Associates held 4,776 shares of Gilead Sciences worth $348K as of Q4 2021.
- Carroll Financial Associates sold 4,145 Gilead Sciences shares in Q4 2021, an estimated $285K.
- Gilead Sciences made up 0.02% of Carroll Financial Associates's portfolio in Q4 2021, its #296 holding.
- Carroll Financial Associates first reported a position in Gilead Sciences in Q2 2013 and has held it in 35 quarters since.
- Carroll Financial Associates's Gilead Sciences position peaked at $1.06M in Q1 2020.
- 1,682 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2021.
Based on Carroll Financial Associates's 13F filing for Q4 2021, filed 6 Jan 2022.